Payment overview · 2025
General Payments
$1,084.54
70 reported records · 11 companies
Healthcare provider profile · identity verified
Dana C Alexander, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MURRAY, KY · NPI 1922061225
Verified facts
What the public records show
CMS Open Payments records show Dana C Alexander, ARNP received $1,084.54 in general payments during 2025 across 70 reported records.
Novo Nordisk Inc accounted for 21.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $228.78 | 21.1% | 18 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $191.39 | 17.6% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $177.32 | 16.4% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $156.98 | 14.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $156.37 | 14.4% | 13 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $64.43 | 5.9% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.64 | 2.7% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.04 | 2.6% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $21.79 | 2.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.96 | 1.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.84 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,039.54 | 69 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $156.98 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $142.89 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $137.98 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $134.75 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $121.11 | 9 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $111.64 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $111.64 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $74.40 | 6 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $64.43 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $50.69 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $46.93 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $46.93 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $35.64 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $34.75 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $30.36 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $29.64 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $28.04 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.79 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $4.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 85 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 63 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 129 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 94 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
63 | 14 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
129 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
72 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
94 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
85 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 516 | 86 |
| Gabapentin | Gabapentin | 368 | 70 |
| Omeprazole | Omeprazole | 362 | 96 |
| Lisinopril | Lisinopril | 335 | 90 |
| Atorvastatin Calcium | Atorvastatin Calcium | 330 | 81 |
| Alprazolam | Alprazolam | 319 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 292 | 73 |
| Amlodipine Besylate | Amlodipine Besylate | 266 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 214 | 58 |
| Furosemide | Furosemide | 213 | 59 |
| Tizanidine Hcl | Tizanidine Hcl | 197 | 44 |
| Famotidine | Famotidine | 185 | 40 |
| Montelukast Sodium | Montelukast Sodium | 166 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 164 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 162 | 43 |
| Ondansetron Odt | Ondansetron | 142 | 33 |
| Losartan Potassium | Losartan Potassium | 141 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 139 | 35 |
| Metformin Hcl | Metformin Hcl | 133 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 131 | 38 |
| Jardiance | Empagliflozin | 129 | 25 |
| Simvastatin | Simvastatin | 127 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 126 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 122 | 51 |
| Pregabalin | Pregabalin | 119 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 117 | 31 |
| Diazepam | Diazepam | 115 | 21 |
| Meloxicam | Meloxicam | 114 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 102 | 17 |
| Glipizide Er | Glipizide | 101 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 100 | 18 |
| Ibuprofen | Ibuprofen | 99 | 26 |
| Tramadol Hcl | Tramadol Hcl | 99 | 26 |
| Ozempic | Semaglutide | 94 | 20 |
| Methylprednisolone | Methylprednisolone | 92 | 64 |
| Potassium Chloride | Potassium Chloride | 92 | 29 |
| Metformin Hcl Er | Metformin Hcl | 91 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 87 | 13 |
| Eliquis | Apixaban | 85 | 15 |
| Buspirone Hcl | Buspirone Hcl | 84 | 20 |
| Sertraline Hcl | Sertraline Hcl | 81 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 80 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 18 |
| Trulicity | Dulaglutide | 72 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 17 |
| Lorazepam | Lorazepam | 71 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 71 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 15 |
| Amoxicillin | Amoxicillin | 67 | 53 |
| Atenolol | Atenolol | 66 | 18 |
| Carvedilol | Carvedilol | 66 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 65 | 22 |
| Farxiga | Dapagliflozin Propanediol | 63 | 14 |
| Trazodone Hcl | Trazodone Hcl | 63 | 18 |
| Promethazine Hcl | Promethazine Hcl | 62 | 14 |
| Doxepin Hcl | Doxepin Hcl | 61 | 14 |
| Allopurinol | Allopurinol | 58 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | 16 |
| Spironolactone | Spironolactone | 57 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 57 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 56 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 16 |
| Finasteride | Finasteride | 50 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 50 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | 11 |
| Celecoxib | Celecoxib | 49 | 13 |
| Glipizide | Glipizide | 49 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | 12 |
| Meclizine Hcl | Meclizine Hcl | 47 | 20 |
| Mounjaro | Tirzepatide | 47 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 25 |
| Temazepam | Temazepam | 46 | suppressed |
| Azithromycin | Azithromycin | 44 | 37 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | suppressed |
| Fluconazole | Fluconazole | 44 | 27 |
| Januvia | Sitagliptin Phosphate | 44 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 43 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 43 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 42 | suppressed |
| Synthroid | Levothyroxine Sodium | 41 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 41 | suppressed |
| Linzess | Linaclotide | 40 | suppressed |
| Prednisone | Prednisone | 40 | 15 |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Estradiol | Estradiol | 38 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Mupirocin | Mupirocin | 37 | 26 |
| Nystatin | Nystatin | 36 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | suppressed |
| Bumetanide | Bumetanide | 35 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 30 |
| Colestipol Hcl | Colestipol Hcl | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | 11 |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Glimepiride | Glimepiride | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Cephalexin | Cephalexin | 28 | 26 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 27 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Moexipril Hcl | Moexipril Hcl | 23 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Nystop | Nystatin | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 14 |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Vraylar | Cariprazine Hcl | 16 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 15 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Kerendia | Finerenone | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Movantik | Naloxegol Oxalate | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,084.54 · 70 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, CAPLYTA, COMIRNATY, ELIQUIS, ENTRESTO, FARXIGA, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, Symbravo, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error